{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:16:11Z","timestamp":1791353771951,"version":"4.3.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,2]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>BCR-ABL\u2013specific CTLs may be obtained by stimulation with peptides derived from BCR-ABL junctional region and alternative splicing. T-cell therapy with BCR-ABL\u2013specific CTLs from healthy donors or patients mediates molecular or hematologic CR in patients with Ph+ ALL.<\/jats:p>","DOI":"10.1182\/blood-2016-07-731091","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T22:20:21Z","timestamp":1481149221000},"page":"582-586","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":54,"title":["BCR-ABL\u2013specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5964-0553","authenticated-orcid":false,"given":"Patrizia","family":"Comoli","sequence":"first","affiliation":[{"name":"Pediatric Hematology\/Oncology and"},{"name":"Cell Factory, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-815X","authenticated-orcid":false,"given":"Sabrina","family":"Basso","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology and"},{"name":"Cell Factory, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Riva","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8936-1114","authenticated-orcid":false,"given":"Patrizia","family":"Barozzi","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Guido","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology and"},{"name":"Cell Factory, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Gurrado","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology and"},{"name":"Cell Factory, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Quartuccio","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology and"},{"name":"Cell Factory, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rubert","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Lagreca","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Vallerini","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Forghieri","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morselli","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bresciani","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cuoghi","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Paolini","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Colaci","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Marasca","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[{"name":"Section of Hematology, University of Ferrara, Ferrara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Iughetti","sequence":"additional","affiliation":[{"name":"Section of Pediatric Hemato-Oncology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Trenti","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Unit\u00e0 Sociosanitaria Locale, Modena, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Narni","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[{"name":"Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8818-1744","authenticated-orcid":false,"given":"Marco","family":"Zecca","sequence":"additional","affiliation":[{"name":"Pediatric Hematology\/Oncology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0373-1154","authenticated-orcid":false,"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2738-6105","authenticated-orcid":false,"given":"Leonardo","family":"Potenza","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliera Universitaria (AOU) Policlinico, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2019111906320917100_B1","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2010-01-242750","article-title":"How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"116","author":"Fielding","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2019111906320917100_B2","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2019111906320917100_B3","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2012.080432","article-title":"Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts","volume":"98","author":"Chiaretti","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"2019111906320917100_B4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"issue":"9","key":"2019111906320917100_B5","first-page":"1275","article-title":"Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission","volume":"90","author":"Potenza","year":"2005","journal-title":"Haematologica"},{"issue":"9","key":"2019111906320917100_B6","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","article-title":"Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111906320917100_B7","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.2016.144535","article-title":"A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study","volume":"101","author":"Chiaretti","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"2019111906320917100_B8","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/blood-2009-06-230391","article-title":"Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment","volume":"115","author":"Riva","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111906320917100_B9","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1038\/bcj.2011.26","article-title":"BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy","volume":"1","author":"Riva","year":"2011","journal-title":"Blood Cancer J"},{"issue":"11","key":"2019111906320917100_B10","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","article-title":"Development and dynamics of robust T-cell responses to CML under imatinib treatment","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"issue":"9460","key":"2019111906320917100_B11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"2019111906320917100_B12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood-2002-02-0360","article-title":"Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome\/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)","volume":"101","author":"Scheuring","year":"2003","journal-title":"Blood"},{"issue":"35","key":"2019111906320917100_B13","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111906320917100_B14","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/0008-5472.CAN-06-3737","article-title":"Alternative BCR\/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches","volume":"67","author":"Volpe","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"2019111906320917100_B15","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood.V87.9.3587.bloodjournal8793587","article-title":"Specific human cellular immunity to bcr-abl oncogene-derived peptides","volume":"87","author":"Bocchia","year":"1996","journal-title":"Blood"},{"issue":"8","key":"2019111906320917100_B16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2011-11-394619","article-title":"Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias","volume":"120","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111906320917100_B17","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood.V98.12.3359","article-title":"Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy","volume":"98","author":"Montagna","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2019111906320917100_B18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrclinonc.2016.41","article-title":"Immunological off-target effects of imatinib","volume":"13","author":"Zitvogel","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"2019111906320917100_B19","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2019111906320917100_B20","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"26","key":"2019111906320917100_B21","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111906320917100_B22","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111906320917100_B23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"22","key":"2019111906320917100_B24","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"Armand","year":"2015","journal-title":"Blood"},{"issue":"18","key":"2019111906320917100_B25","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/5\/582\/1401537\/blood731091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/5\/582\/1401537\/blood731091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T06:34:14Z","timestamp":1574145254000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/5\/582\/36170\/BCRABLspecific-Tcell-therapy-in-Ph-ALL-patients-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,2]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,2,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-07-731091","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,2]]}}}